Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults

American Journal of Psychiatry

Volumn 174, Issue 5, 2017, Pages 468-475

  Marshe, Victoria S ^{a,b,c,d,e,f,g}   Maciukiewicz, Malgorzata ^{a,b,c,d,e,f,g}   Rej, Soham ^{a,b,c,d,e,f,g}   Tiwari, Arun K ^{a,b,c,d,e,f,g}   Sibille, Etienne ^{a,b,c,d,e,f,g}   Blumberger, Daniel M ^{a,b,c,d,e,f,g}   Karp, Jordan F ^{a,b,c,d,e,f,g}   Lenze, Eric J ^{a,b,c,d,e,f,g}   Reynolds, Charles F ^{a,b,c,d,e,f,g}   Kennedy, James L ^{a,b,c,d,e,f,g}   Mulsant, Benoit H ^{a,b,c,d,e,f,g}   Müller, Daniel J ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN TRANSPORTER; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE 2; VENLAFAXINE; GENETIC MARKER; SLC6A2 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DOSE TITRATION; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NOREPINEPHRINE TRANSPORTER GENE; PHARMACOGENETICS; REMISSION; SEROTONIN RECEPTOR 1A GENE; SEROTONIN RECEPTOR 1B GENE; SEROTONIN RECEPTOR 2A GENE; SEROTONIN RECEPTOR 2C GENE; SEROTONIN TRANSPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL CORTEX; THALAMUS; TRYPTOPHAN HYDROXYLASE 1 GENE; TRYPTOPHAN HYDROXYLASE 2 GENE; AGED; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; QUANTITATIVE TRAIT LOCUS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOTYPE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUANTITATIVE TRAIT LOCI; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 85018391652     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16050617     Document Type: Article

References (39)

1. Whyte EM, Basinski J, Farhi P, et al: Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1634-1641
2. Lenze EJ, Schulz R, Martire LM, et al: The course of functional decline in older people with persistently elevated depressive symptoms: longitudinal findings from the Cardiovascular Health Study. J Am Geriatr Soc 2005; 53:569-575
3. ReynoldsCF3rd,DewMA,Pollock BG, et al: Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130-1138
4. Fabbri C, Porcelli S, Serretti A: From pharmacogenetics to pharmacogenomics: The way toward the personalization of antidepressant treatment. Can J Psychiatry 2014; 59:62-75
5. Joel I, Begley AE, Mulsant BH, et al: Dynamic prediction of treatment response inlate-lifedepression.AmJGeriatr Psychiatry 2014; 22:167-176
6. Melichar JK, Haida A, Rhodes C, et al: Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. J Psychopharmacol 2001; 15:9-12
7. Lee SH, Choi TK, Lee E, et al: Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 2010; 62:198-206
8. Ng C, Sarris J, Singh A, et al: Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 2013; 28:516-522
9. Higuchi H, Takahashi H, Kamata M, et al: Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. Neuropsychiatr Dis Treat 2009; 5:393-398
10. Perlis RH, Fijal B, Dharia S, et al: Failure to replicate genetic associations with antidepressant treatment response in duloxetinetreated patients. Biol Psychiatry 2010; 67:1110-1113
11. Yoshida K, Takahashi H, Higuchi H, et al: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575-1580
12. Lohoff FW, Narasimhan S, Rickels K: Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2013; 13: 464-469
13. Wang H-C, Yeh TL, Chang HH, et al: TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl) 2011; 213:773-779
14. Lenze EJ, Mulsant BH, Blumberger DM, et al: Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: A randomised, doubleblind, placebo-controlled trial. Lancet 2015; 386:2404-2412
15. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
16. Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983; 40:812
17. Hahn MK, Blackford JU, Haman K, et al: Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Genes Brain Behav 2008; 7:487-495
18. Villafuerte SM, Vallabhaneni K, Sliwerska E, et al: SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009; 19:281-291
19. Illi A, Setälä-SoikkeliE, ViikkiM,et al:5-HTR1A,5-HTR2A,5-HTR6, TPH1, and TPH2 polymorphisms and major depression. Neuroreport 2009; 20:1125-1128
20. Xu Z, Zhang Z, Shi Y, et al: Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol 2012; 26:349-359
21. Zhang K, Xu Q, Xu Y, et al: The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. J Affect Disord 2009; 114:224-231
22. Arias B, Fabbri C, Gressier F, et al: TPH1,MAOA, serotonin receptor 2Aand2Cgenes in citalopramresponse:possible effect inmelancholic and psychotic depression. Neuropsychobiology 2013; 67:41-47
23. Scheuch K, Lautenschlager M, Grohmann M, et al: Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 2007; 62:1288-1294
24. Zhang X, Gainetdinov RR, Beaulieu JM, et al: Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005; 45:11-16
25. Purcell S, Neale B, Todd-Brown K, et al: PLINK: A tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575
26. Anderson CA, Pettersson FH, Clarke GM, et al: Data quality control in genetic case-control association studies. Nat Protoc 2010; 5: 1564-1573
27. Nassir R, Kosoy R, Tian C, et al: An ancestry informative marker set for determining continental origin: validation and extension using human genome diversity panels. BMC Genet 2009; 10:39
28. Kosoy R, Nassir R, Tian C, et al: Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat 2009; 30:69-78
29. Price AL, Patterson NJ, Plenge RM, et al: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909
30. Aulchenko YS, Ripke S, Isaacs A, et al: GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007; 23: 1294-1296
31. Pinheiro J, Bates D, DebRoy S, et al: nlme: Linear and Nonlinear Mixed Effects Models, 2012 (https://cran.r-project.org/web/packages/nlme/index.html)
32. van Buuren S, Groothui-Oudshoorn K: MICE: multivariate imputation by chained equations in R. J Stat Softw 2011; 45:67
33. Gauderman W, Morrison J: QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. 2006 (http://biostats.usc.edu/software)
34. Ward LD, Kellis M: HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40:D930-D934
35. Trabzuni D, Ryten M, Walker R, et al: Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. JNeurochem 2011; 119:275-282
36. Kim YK, Hwang JA, Lee HJ, et al: Association between norepinephrine transporter gene (SLC6A2) polymorphisms and suicide in patients with major depressive disorder. J Affect Disord 2014; 158: 127-132
37. Singh AB, Bousman CA, Ng CH, et al: Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: A pilot study. Clin Psychopharmacol Neurosci 2015; 13:53-61
38. Niitsu T, Fabbri C, Bentini F, et al: Pharmacogenetics in major depression: A comprehensivemeta-analysis. ProgNeuropsychopharmacol Biol Psychiatry 2013; 45:183-194
39. Lenze EJ, Sheffrin M, Driscoll HC, et al: Incomplete response in late-life depression: getting to remission. Dialogues Clin Neurosci 2008; 10:419-430